Motor and non-motor fluctuations

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 159-

  Fox, Susan H ^a   Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649327177     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84039-5     Document Type: Chapter

References (330)

1. Aarsland D., Tandberg E., Larsen J.P., et al. Frequency of dementia in Parkinson disease. Arch Neurol 53 (1996) 538-542
2. Abe K., Takanashi M., and Yanagihara T. Fatigue in patients with Parkinson's disease. Behav Neurol 12 (2000) 103-106
3. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
4. Ahlskog J.E., Muenter M.D., McManis P.G., et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 63 (1988) 876-886
5. Alexander G.M., Schwartzman R.J., Grothusen J.R., et al. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology 44 (1994) 1491-1499
6. Alves G., Wentzel-Larsen T., and Larsen J.P. Is fatigue an independent and persistent symptom in patients with Parkinson disease?. Neurology 63 (2004) 1908-1911
7. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 (1999) 461-474
8. Arnulf I., Bonnet A.M., Damier P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
9. Assal F., Spahr L., Hadengue A., et al. Tolcapone and fulminant hepatitis. Lancet 352 (1998) 958
10. Aubert I., Guigoni C., Hakansson K., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
11. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
12. Bara-Jimènez W., Morris M., Dimitrova T., et al. Alpha 2A adrenergic antagonistic effects in advanced Parkinson's diseases. 8th International Congress of Parkinson's Disease and Movement Disorders, 14th-17th June 2004, Rome, Italy (2004)
13. Baratti M., and Calzetti S. Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 47 (1984) 1241-1243
14. Baruzzi A., Contin M., Riva R., et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 10 (1987) 527-537
15. Bateson M.C., Gibberd F.B., and Wilson R.S. Salivary symptoms in Parkinson disease. Arch Neurol 29 (1973) 274-275
16. Bejjani B.P., Arnulf I., Demeret S., et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?. Ann Neurol 47 (2000) 655-658
17. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
18. Blanchet P.J., Calon F., Martel J.C., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 (1995) 854-859
19. Bojo L., and Cassuto J. Gastric reflex relaxation by colonic distension. J Auton Nerv Syst 38 (1992) 57-64
20. Boucai L., Cerquetti D., and Merello M. Functional surgery for Parkinson's disease treatment: a structured analysis of a decade of published literature. Br J Neurosurg 18 (2004) 213-222
21. Braak H., Ghebremedhin E., Rub U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 (2004) 121-134
22. Bravi D., Mouradian M.M., Roberts J.W., et al. End-of-dose dystonia in Parkinson's disease. Neurology 43 (1993) 2130-2131
23. Bravi D., Mouradian M.M., Roberts J.W., et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36 (1994) 27-31
24. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14 (1995) 187-202
25. Brotchie J.M., Lee J., and Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 112 3 (2005) 359-391
26. Brown R.G., Marsden C.D., Quinn N., et al. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 47 (1984) 454-465
27. Brown R.G., Dittner A., Findley L., et al. The Parkinson fatigue scale. Parkinsonism Relat Disord 11 (2005) 49-55
28. Bushmann M., Dobmeyer S.M., Leeker L., et al. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 39 (1989) 1309-1312
29. Buzas B., and Max M.B. Pain in Parkinson disease. Neurology 62 (2004) 2156-2157
30. Calabresi P., Giacomini P., Centonze D., et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann Neurol 47 4 Suppl 1 (2000) S60-S68
31. Calon F., Morissette M., Ghribi O., et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 127-138
32. Calon F., Birdi S., Rajput A.H., et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 (2002) 186-196
33. Calon F., Morissette M., Rajput A.H., et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18 (2003) 241-253
34. Cantello R., Gilli M., Riccio A., et al. Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry 49 (1986) 1182-1190
35. Carter J.H., Nutt J.G., Woodward W.R., et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 39 (1989) 552-556
36. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50 5 Suppl 5 (1998) S17-S25
37. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 55 Suppl 1 (1998) 1-9
38. Chase T.N., Mouradian M.M., and Engber T.M. Motor response complications and the function of striatal efferent systems. Neurology 43 12 Suppl 6 (1993) S23-S27
39. Chaudhuri K.R., and Clough C. Subcutaneous apomorphine in Parkinson's disease. BMJ 316 (1998) 641
40. Chaudhuri K.R., Critchley P., Abbott R.J., et al. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 2 8622 (1988) 1260
41. Christmas T.J., Kempster P.A., Chapple C.R., et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2 (1988) 1451-1453
42. Chudler E.H., and Dong W.K. The role of the basal ganglia in nociception and pain. Pain 60 (1995) 3-38
43. Clarke A., Brewer F., Johnson E.S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110 (2003) 1241-1255
44. Clarke C.E., and Deane K. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) CD001517
45. Clarke C.E., and Deane K. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) CD001519
46. Clarke C.E., and Speller J.M. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev (2000) CD000236
47. Clarke C.E., Speller J.M., and Clarke J.A. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2000) CD002259.2000
48. Colosimo C., Merello M., Hughes A.J., et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 60 (1996) 634-637
49. Colzi A., Turner K., and Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 573-576
50. Comella C.L., and Goetz C.G. Akathisia in Parkinson's disease. Mov Disord 9 (1994) 545-549
51. Comella C.L., Tanner C.M., and Ristanovic R.K. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34 (1993) 710-714
52. Contin M., Riva R., Martinelli P., et al. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 54 (1998) 303-308
53. Cooper J.A., Sagar H.J., Jordan N., et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 114 (1991) 2095-2122
54. Corbin D.O., and Williams A.C. Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 50 (1987) 821-822
55. Cotzias G.C., Papavasiliou P.S., Fehling C., et al. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med 282 (1970) 31-33
56. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5 (1990) 100-108
57. Currie L.J., Harrison M.B., Trugman J.M., et al. Early morning dystonia in Parkinson's disease. Neurology 51 (1998) 283-285
58. De Keyser J., and Vincken W. L-dopa-induced respiratory disturbance in Parkinson's disease suppressed by tiapride. Neurology 35 (1985) 235-237
59. de la Fuente-Fernandez R., Lu J.Q., Sossi V., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49 (2001) 298-303
60. de la Fuente-Fernandez R., Sossi V., Huang Z., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
61. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 (2001) 956-963
62. Delis D., Direnfeld L., Alexander M.P., et al. Cognitive fluctuations associated with on-off phenomenon in Parkinson disease. Neurology 32 (1982) 1049-1052
63. Dewey Jr. R.B., Hutton J.T., LeWitt P.A., et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58 (2001) 1385-1392
64. Djaldetti R., Baron J., Ziv I., et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 46 (1996) 1051-1054
65. Djaldetti R., Shifrin A., Rogowski Z., et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 62 (2004) 2171-2175
66. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21 (2001) 5546-5558
67. Duvoisin R.C. Variations in the "on-off" phenomena. Adv Neurol 5 (1974) 339-340
68. Edwards L.L., Quigley E.M., and Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42 (1992) 726-732
69. Engber T.M., Susel Z., Juncos J.L., et al. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168 3 (1989) 291-298
70. Evans M.A., Broe G.A., Triggs E.J., et al. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31 (1981) 1288-1294
71. Evans A.H., Katzenschlager R., Paviour D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
72. Fabbrini G., Mouradian M.M., Juncos J.L., et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24 (1988) 366-371
73. Factor S.A., and Friedman J.H. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12 (1997) 483-496
74. Factor S.A., Brown D.L., and Molho E.S. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 15 (2000) 167-169
75. Factor S.A., Molho E.S., Feustel P.J., et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 24 (2001) 295-299
76. Factor S.A., Feustel P.J., Friedman J.H., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60 (2003) 1756-1761
77. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effects of intramuscular pyridoxine. Neurology 24 (1974) 431-441
78. Fahn S. Episodic failure of absorption of levodopa: a factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 27 (1977) 390
79. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders (1982), Butterworth Scientific, London 123-145
80. Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 67 (1995) 53-63
81. Fahn S., Oakes D., Shoulson I., et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
82. Fenelon G., Mahieux F., Huon R., et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123 (2000) 733-745
83. Finberg J.P., Lamensdorf I., Weinstock M., et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 80 (1999) 495-499
84. Fitzmaurice H., Fowler C.J., Rickards D., et al. Micturition disturbance in Parkinson's disease. Br J Urol 57 (1985) 652-656
85. Ford B., Louis E.D., Greene P., et al. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 11 (1996) 421-426
86. Forsberg M., Lehtonen M., Heikkinen M., et al. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther 304 (2003) 498-506
87. Fox S., Silverdale M., Kellett M., et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 19 (2004) 554-560
88. Frankel J.P., Lees A.J., Kempster P.A., et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 96-101
89. Friedman A., and Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 84 (1991) 111-113
90. Friedman J., and Friedman H. Fatigue in Parkinson's disease. Neurology 43 (1993) 2016-2018
91. Friedman J.H. Punding on levodopa. Biol Psychiatry 36 (1994) 350-351
92. Funkiewiez A., Ardouin C., Caputo E., et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (2004) 834-839
93. Gancher S.T., Nutt J.G., and Woodward W.R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 10 (1995) 37-43
94. Giladi N., McMahon D., Przedborski S., et al. Motor blocks in Parkinson's disease Neurology 42 (1992) 333-339
95. Giladi N., Kao R., and Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 12 (1997) 302-305
96. Giovannoni G., O'Sullivan J.D., Turner K., et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
97. Girotti F., Carella F., Grassi M.P., et al. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 49 (1986) 657-660
98. Golbe L.I., Lieberman A.N., Muenter M.D., et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 11 (1988) 45-55
99. Goetz C.G. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol 91 (2003) 213-228
100. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
101. Goetz C.G., Lutge W., and Tanner C.M. Autonomic dysfunction in Parkinson's disease. Neurology 36 (1986) 73-75
102. Goetz C.G., Tanner C.M., Levy M., et al. Pain in Parkinson's disease. Mov Disord 1 (1986) 45-49
103. Goetz C.G., Pappert E.J., Blasucci L.M., et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50 (1998) 515-517
104. Goetz C.G., Wuu J., Curgian L.M., et al. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 64 (2005) 81-86
105. Gordin A., Kaakkola S., and Teravainen H. In: Gordin A., Kaakkola S., and Teravainen H. (Eds). Position of COMT inhibition in the treatment of Parkson's disease Vol. 91 (2003), Lippincott Williams and Williams, USA 237-250
106. Gotham A.M., Brown R.G., and Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 111 (1988) 299-321
107. Graham J.M., Grunewald R.A., and Sagar H.J. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 63 (1997) 434-440
108. Green J., McDonald W.M., Vitek J.L., et al. Cognitive impairments in advanced PD without dementia. Neurology 59 (2002) 1320-1324
109. Gulati A., Alison F., Frauke S., et al. A clinical observational study of the patterns and occurrence of non-motor symptoms in Parkinson's disease ranging from early to advanced disease. Mov Disord 19 Suppl 9 (2004) 406
110. Gunal D.I., Nurichalichi K., Tuncer N., et al. The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 29 (2002) 61-64
111. Hadj Tahar A., Gregoire L., Bangassoro E., et al. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 23 (2000) 195-202
112. Harding A.J., Stimson E., Henderson J.M., et al. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125 (2002) 2431-2445
113. Hardoff R., Sula M., Tamir A., et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 16 (2001) 1041-1047
114. Hagelberg N., Martikainen I.K., Mansikka H., et al. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 99 (2002) 273-279
115. Hauser R.A., and Holford N.H. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 17 (2002) 961-968
116. Hauser R.A., Koller W.C., Hubble J.P., et al. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 15 (2000) 485-489
117. Henry B., and Brotchie J.M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 9 (1996) 149-158
118. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155 (1999) 204-220
119. Henry B., Duty S., Fox S.H., et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 183 (2003) 458-468
120. Herlofson K., and Larsen J.P. Measuring fatigue in patients with Parkinson's disease-the Fatigue Severity Scale. Eur J Neurol 9 (2002) 595-600
121. Hillen M.E., and Sage J.L. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 47 (1996) 1180-1183
122. Hoehn M.M., and Elton R.L. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 35 (1985) 199-206
123. Honey C.R., Stoessl A.J., Tsui J.K., et al. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg 91 (1999) 198-201
124. Horstink M.W., Zijlmans J.C., Pasman J.W., et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 53 (1990) 224-226
125. Huber S.J., Shulman H.G., Paulson G.W., et al. Fluctuations in plasma dopamine level impair memory in Parkinson's disease. Neurology 37 (1987) 1371-1375
126. Huber S.J., Shulman H.G., Paulson G.W., et al. Dose-dependent memory impairment in Parkinson's disease. Neurology 39 (1989) 438-440
127. Hughes A.J., Bishop S., Lees A.J., et al. Rectal apomorphine in Parkinson's disease. Lancet 337 (1991) 118
128. Hughes A.J., Bishop S., Kleedorfer B., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 8 (1993) 165-170
129. Ilson J., Fahn S., and Cote L. Painful dystonic spasms in Parkinson's disease. Adv Neurol 40 (1984) 395-398
130. Isella V., Melzi P., Grimaldi M., et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 17 (2002) 366-371
131. Jankovic J., and Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology 36 (1986) 303-304
132. Kaakkola S., Gordin A., and Mannisto P.T. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 25 (1994) 813-824
133. Kapoor R., Turjanski N., Frankel J., et al. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 1015
134. Karstaedt P.J., and Pincus J.H. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 49 (1992) 149-151
135. Kedia S., Moro E., Tagliati M., et al. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 63 (2004) 2410-2412
136. Kempster P.A., Lees A.J., Crichton P., et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 4 (1989) 47-52
137. Keshavan M.S., David A.S., Narayanen H.S., et al. "On-off" phenomena and manic-depressive mood shifts: case report. J Clin Psychiatry 47 (1986) 93-94
138. Keyser D.L., and Rodnitzky R.L. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151 (1991) 794-796
139. Khan N.L., Graham E., Critchley P., et al. Parkin disease: a phenotypic study of a large case series. Brain 126 (2003) 1279-1292
140. Koike Y., and Takahashi A. Autonomic dysfunction in Parkinson's disease. Eur Neurol 38 Suppl 2 (1997) 8-12
141. Koller W., Guarnieri M., Hubble J., et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 112 (2005) 221-230
142. Koller W.C. Sensory symptoms in Parkinson's disease. Neurology 34 (1984) 957-959
143. Kompoliti K., Goetz C.G., Leurgans S., et al. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord 15 (2000) 309-312
144. Korchounov A., Kessler K.R., and Schipper H.I. Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease. Acta Neurol Scand 109 (2004) 45-51
145. Korlipara L.V., Cooper J.M., and Schapira A.H. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology 46 (2004) 562-569
146. Krack P., Pollak P., Limousin P., et al. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 122 (1999) 1133-1146
147. Krack P., Batir A., Van Blercom N., et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 (2003) 1925-1934
148. Krupp L.B., and Pollina D.A. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 9 (1996) 456-460
149. Kumar R., Lozano A.M., Kim Y.J., et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51 (1998) 850-855
150. Kumar R., Lang A.E., Rodriguez-Oroz M.C., et al. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology 55 12 Suppl 6 (2000) S34-S39
151. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 19 (2004) 433-437
152. Kurlan R., Rubin A.J., Miller C., et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20 (1986) 262-265
153. Kurth M.C., Tetrud J.W., Irwin I., et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 43 (1993) 1036-1039
154. Kurth M.C., Tetrud J.W., Tanner C.M., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43 (1993) 1698-1703
155. Kurth M.C., Adler C.H., Hilaire M.S., et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48 (1997) 81-87
156. Lagrange E., Krack P., Moro E., et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 59 (2002) 1976-1978
157. Lang A.E., and Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 37 (1987) 477-481
158. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
159. Langston J.W., and Forno L.S. The hypothalamus in Parkinson disease. Ann Neurol 3 (1978) 129-133
160. Lawrence A.D., Evans A.H., and Lees A.J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurol 2 (2003) 595-604
161. Leenders K.L., Poewe W.H., Palmer A.J., et al. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20 (1986) 258-262
162. Lees A.J. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. Eur Neurol 27 Suppl 1 (1987) 126-134
163. Lees A.J. The on-off phenomenon. J Neurol Neurosurg Psychiatry Suppl (Jun:1989) 29-37
164. Lees A.J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 7 3-4 (1993) 121-128
165. Lees A.J., Shaw K.M., Kohout L.J., et al. Deprenyl in Parkinson's disease. Lancet 2 8042 (1977) 791-795
166. Lees A.J., Shaw K.M., and Stern G.M. Baclofen in Parkinson's disease. J Neurol Neurosurg Psychiatry 41 (1978) 707-708
167. LeWitt P.A., Burns R.S., and Newman R.P. Dystonia in untreated parkinsonism. Clin Neuropharmacol 9 (1986) 293-297
168. Lieberman A., Gopinathan G., Miller E., et al. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur Neurol 30 (1990) 75-78
169. Lieberman A., Imke S., Muenter M., et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 43 (1993) 1981-1984
170. Limousin P., Krack P., Pollak P., et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339 (1998) 1105-1111
171. Loher T.J., Burgunder J.M., Pohle T., et al. Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study. J Neurosurg 96 (2002) 844-853
172. Luquin M.R., Scipioni O., Vaamonde J., et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7 (1992) 117-124
173. MacMahon D.G., Sachdev D., Boddie H.G., et al. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 220-223
174. Mancini F., Zangaglia R., Cristina S., et al. Double-blind placebo controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688
175. Manford M., and Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 121 (1998) 1819-1840
176. Manson A.J., Katzenschlager R., Hobart J., et al. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry 70 (2001) 554-556
177. Manson A.J., Turner K., and Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17 (2002) 1235-1241
178. Maricle R.A., Nutt J.G., Valentine R.J., et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 45 (1995) 1757-1760
179. Marras C., and Lang A.E. Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003) 143-146
180. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiatry 57 (1994) 672-681
181. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 (1976) 292-296
182. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 8007 (1977) 345-349
183. Marsden C.D., Parkes J.D., and Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders (1982), Butterworth Scientific, London 96-122
184. Mathers S.E., Kempster P.A., Law P.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 46 (1989) 1061-1064
185. Mathias C.J., and Kimber J.R. Treatment of postural hypotension. J Neurol Neurosurg Psychiatry 65 (1998) 285-289
186. Matison R., Mayeux R., Rosen J., et al. "Tip-of-the-tongue" phenomenon in Parkinson disease. Neurology 32 (1982) 567-570
187. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
188. Meco G., Bonifati V., Bedini L., et al. Relations between on-off phenomena and cognitive functions in Parkinson disease. Ital J Neurol Sci 12 (1991) 57-62
189. Melamed E. Early morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 36 (1979) 308-310
190. Melamed E., and Bitton V. Delayed onset of responses to individual doses of L-dopa in parkinsonian fluctuators: an additional side effect of long-term L-dopa therapy. Neurology 34 Suppl 2 (1984) 270
191. Melamed E., Hefti F., and Wurtman R.J. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8 (1980) 558-563
192. Meltzer H.Y. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry Suppl 17 (1992) 22-29
193. Menza M.A., Sage J., Marshall E., et al. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 5 (1990) 148-151
194. Merello M., and Lees A.J. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992) 1024-1026
195. Merims D., Shabtai H., Korczyn A.D., et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 111 (2004) 1447-1453
196. Mohr E., Fabbrini G., Williams J., et al. Dopamine and memory function in Parkinson's disease. Mov Disord 4 (1989) 113-120
197. Molina J.A., Sainz-Artiga M.J., Fraile A., et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord 15 (2000) 869-872
198. Molinuevo J.L., Valldeoriola F., Tolosa E., et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol 57 (2000) 983-988
199. Montastruc J.L., Rascol O., Senard J.M., et al. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 14 (1991) 432-437
200. Moro E., Scerrati M., Romito L.M., et al. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53 (1999) 85-90
201. Moro E., Esselink R.J., Benabid A.L., et al. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 125 (2002) 2408-2417
202. Moskovitz C., Moses III H., and Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135 (1978) 669-675
203. Mouradian M.M., Juncos J.L., Fabbrini G., et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 24 (1988) 372-378
204. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18 (2003) 738-750
205. Muenter M.D., and Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46 (1971) 231-239
206. Muenter M.D., Sharpless N.S., Tyce G.M., et al. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to I-dopa therapy in Parkinson's disease. Mayo Clin Proc 52 (1977) 163-174
207. Muller T., Woitalla D., Schulz D., et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm 107 (2000) 113-119
208. Myllyla V.V., Kultalahti E.R., Haapaniemi H., et al. FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 8 (2001) 53-60
209. Nausieda P.A., Weiner W.J., Kaplan L.R., et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5 (1982) 183-194
210. Ng K.Y., Colburn R.W., and Kopin I.J. Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 230 (1971) 331-332
211. Nissenbaum H., Quinn N.P., Brown R.G., et al. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 17 (1987) 899-904
212. Nutt J.G. Levodopa-induced dyskinesia:review, observation and speculations. Neurology 40 (1990) 340-345
213. Nutt J.G., and Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 7 (1984) 35-49
214. Nutt J.G., and Holford N.H. The response to levodopa in Parkinson's disease:imposing pharmacological law and order. Ann Neurol 39 (1996) 561-573
215. Nutt J.G., and Nygaard T.G. Response to L-DOPA in DOPA-responsive dystonia. Arch Neurol 58 6 (2001) 905-910
216. Nutt J.G., Woodward W.R., Hammerstad J.P., et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 310 (1984) 483-488
217. Nutt J.G., Gancher S.T., and Woodward W.R. Does an inhibitory action of levodopa contribute to motor fluctuations?. Neurology 38 (1988) 1553-1557
218. Nutt J.G., Woodward W.R., Carter J.H., et al. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49 (1992) 1123-1130
219. Nutt J.G., Woodward W.R., Beckner R.M., et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
220. Nutt J.G., Carter J.H., Lea E.S., et al. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 12 (1997) 285-292
221. Nutt J.G., Obeso J.A., and Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S109-S115
222. Nutt J.G., Carter J.H., Lea E.S., et al. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 51 (2002) 686-693
223. Nyholm D., Nilsson Remahl A.I., Dizdar N., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
224. Obeso J.A., Rodriguez-Oroz M.C., Chana P., et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 55 11 Suppl 4 (2000) S13-S20
225. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S8-S19
226. Oh J.D., Vaughan C.L., and Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 821 (1999) 433-442
227. Olanow C.W., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 50 3 Suppl 3 (1998) S1-S57
228. Olanow C.W., Fahn S., Muenter M., et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9 (1994) 40-47
229. Olanow C.W., Hauser R.A., Gauger L., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 (1995) 771-777
230. Olanow C.W., Damier P., Goetz C.G., et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27 (2004) 58-62
231. Ondo W.G., Hunter C., and Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 (2004) 37-40
232. Pacchetti C., Albani G., Martignoni E., et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10 (1995) 333-336
233. Papa S.M., and Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39 (1996) 574-578
234. Papa S.M., Engber T.M., Kask A.M., et al. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662 (1994) 69-74
235. Papa S.M., Boldry R.C., Engber T.M., et al. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701 (1995) 13-18
236. Pappert E.J., Goetz C.G., Niederman F.G., et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 14 (1999) 117-121
237. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 (1997) 747-755
238. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 60 (2003) 1721-1728
239. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62 (2005) 241-248
240. Pearce R.K., Heikkila M., Linden I.B., et al. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 156 (2001) 402-409
241. Peppe A., Pierantozzi M., Bassi A., et al. Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. J Neurosurg 101 (2004) 195-200
242. Pfeiffer R.F., and Sucha E.L. "On-off"-induced lethal hyperthermia. Mov Disord 4 (1989) 338-341
243. Piccini P., Weeks R.A., and Brooks D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42 (1997) 720-726
244. Picconi B., Centonze D., Hakansson K., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
245. Pincus J.H., and Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 44 (1987) 270-272
246. Pinter M.M., Pogarell O., and Oertel W.H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 66 (1999) 436-441
247. Pluck G.C., and Brown R.G. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 73 (2002) 636-642
248. Poewe W. Psychosis in Parkinson's disease. Mov Disord 18 Suppl 6 (2003) S80-S87
249. Poewe W., and Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 63 8 Suppl 3 (2004) S12-S16
250. Poewe W., Berger W., Benke T., et al. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 29 (1991) 670-673
251. Poewe W.H., Lees A.J., and Stern G.M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 23 (1988) 73-78
252. Poewe W.H., Deuschl G., Gordin A., et al. Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 (2002) 245-255
253. Priano L., Albani G., Brioschi A., et al. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov Disord 19 (2004) 937-942
254. Quattrone A., Zappia M., Aguglia U., et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 38 (1995) 389-395
255. Quinn N., and Marsden C.D. Lithium for painful dystonia in Parkinson's disease. Lancet 1 (1986) 1377
256. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 51 2 Suppl 2 (1998) S25-S29
257. Quinn N.P., Koller W.C., Lang A.E., et al. Painful Parkinson's disease. Lancet 1 8494 (1986) 1366-1369
258. Rabey J.M., Sagi I., Huberman M., et al. Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23 (2000) 324-330
259. Racette B.A., Hartlein J.M., Hershey T., et al. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 14 (2002) 438-442
260. Rajput A.H., Martin W., Saint-Hilaire M.H., et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49 (1997) 1066-1071
261. Rajput A.H., Fenton M.E., Di Paolo T., et al. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord 10 (2004) 221-226
262. Rascol O., Fabre N., Blin O., et al. Naltrexone, an opiate antagonists, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 9 (1994) 437-440
263. Rascol O., Lees A.J., Senard J.M., et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 19 (1996) 234-245
264. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
265. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 104 (2001) 312-315
266. Reuter I., Ellis C.M., and Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100 (1999) 163-167
267. Richard I.H., Frank S., McDermott M.P., et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 17 (2004) 201-207
268. Riederer P., and Youdim M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46 (1986) 1359-1365
269. Riley D.E., and Lang A.E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 43 (1993) 1459-1464
270. Rinne J.O., Laihinen A., Lonnberg P., et al. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 556 (1991) 117-122
271. Ruottinen H.M., and Rinne U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19 (1996) 222-233
272. Ruottinen H.M., and Rinne U.K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60 (1996) 36-40
273. Sage J.I. Pain in Parkinson's disease. Curr Treat Options Neurol 6 (2004) 191-200
274. Sage J.I., and Mark M.H. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Ann Neurol 37 (1995) 120-122
275. Sage J.I., Trooskin S., Sonsalla P.K., et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24 (1988) 87-89
276. Sage J.I., Kortis H.I., and Sommer W. Evidence for the role of spinal cord systems in Parkinson's disease-associated pain. Clin Neuropharmacol 13 (1990) 171-174
277. Saint-Cyr J.A., Taylor A.E., and Lang A.E. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 43 12 Suppl 6 (1993) S47-S52
278. Samadi P., Gregoire L., and Bedard P.J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45 (2003) 954-963
279. Sanchez-Ramos J.R., Ortoll R., and Paulson G.W. Visual hallucinations associated with Parkinson disease. Arch Neurol 53 (1996) 1265-1268
280. Schrag A., Ben-Shlomo Y., and Quinn N. How common are complications of Parkinson's disease?. J Neurol 249 (2002) 419-423
281. Seager H. Drug delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 50 (1997) 375-382
282. Seif C., Herzog J., van der Horst C., et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 55 (2004) 118-120
283. Senard J.M., Rai S., Lapeyre-Mestre M., et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 63 (1997) 584-589
284. Shoulson I., Glaubiger G.A., and Chase T.N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25 (1975) 1144-1148
285. Shulman L.M., Taback R.L., Bean J., et al. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 16 (2001) 507-510
286. Siemers E.R., Shekhar A., Quaid K., et al. Anxiety and motor performance in Parkinson's disease. Mov Disord 8 (1993) 501-506
287. Sieradzan K.A., Fox S.H., Hill M., et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001) 2108-2111
288. Silverdale M.A., Fox S.H., Crossman A.R., et al. Potential nondopaminergic drugs for Parkinson's disease. Adv Neurol 91 (2003) 273-291
289. Simon N., Gantcheva R., Bruguerolle B., et al. The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease. Parkinsonism Relat Disord 10 (2004) 137-142
290. Snider S.R., Fahn S., Isgreen W.P., et al. Primary sensory symptoms in parkinsonism. Neurology 26 (1976) 423-429
291. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 6 (2005) 726-733
292. Steiger M.J., Quinn N.P., Toone B., et al. Off-period screaming accompanying motor fluctuations in Parkinson's disease. Mov Disord 6 (1991) 89-90
293. Stein W.M., and Read S. Chronic pain in the setting of Parkinson's disease and depression. J Pain Symptom Manage 14 (1997) 255-258
294. Stibe C.M., Lees A.J., Kempster P.A., et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1 8582 (1988) 403-406
295. Stolze H., Klebe S., Poepping M., et al. Effects of bilateral subthalamic nucleus stimulation on parkinsonian gait. Neurology 57 (2001) 144-146
296. Stocchi F., Quinn N.P., Barbato L., et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol 17 (1994) 38-44
297. Stocchi F., Nordera G., and Marsden C.D. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 20 (1997) 95-115
298. Stocchi F., Vacca L., Berardelli A., et al. Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord 16 (2001) 301-305
299. Stocchi F., Vacca L., De Pandis M.F., et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 22 (2001) 93-94
300. Stocchi F., Ruggieri S., Vacca L., et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 Pt 9 (2002) 2058-2066
301. Struck L.K., Rodnitzky R.L., and Dobson J.K. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 40 (1990) 467-470
302. Swinn L., Schrag A., Viswanathan R., et al. Sweating dysfunction in Parkinson's disease. Mov Disord 18 (2003) 1459-1463
303. Syed N., Murphy J., Zimmerman Jr. T., et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13 (1998) 336-338
304. Tetrud J.W., and Koller W.C. A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology 63 7 Suppl 2 (2004) S2-S6
305. Togasaki D.M., Tan L., Protell P., et al. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 50 (2001) 254-257
306. Torstenson R., Hartvig P., Langstrom B., et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 41 (1997) 334-340
307. Tracey I., Becerra L., Chang I., et al. Noxious hot and cold stimulation produce common patterns of brain activation in humans: a functional magnetic resonance imaging study. Neurosci Lett 288 (2000) 159-162
308. Trosch R.M., Friedman J.H., Lannon M.C., et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 13 (1998) 377-382
309. Turjanski N., Lees A.J., and Brooks D.J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49 (1997) 717-723
310. Tyne H.L., Parsons J., Sinnott A., et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol 251 (2004) 1370-1374
311. Uchiyama T., Sakakibara R., Hattori T., et al. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 18 (2003) 573-578
312. van Hilten J.J., Weggeman M., van der Velde E.A., et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect 5 (1993) 235-244
313. Varma T.R., Fox S.H., Eldridge P.R., et al. Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry 74 (2003) 170-174
314. Vazquez A., Jimenez-Jimenez F.J., Garcia-Ruiz P., et al. "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand 87 (1993) 14-18
315. Velasco M., and Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5 (1998) 37-43
316. Verhagen Metman L., Locatelli E.R., Bravi D., et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48 (1997) 369-372
317. Verhagen-Metman L., Del Dotto P., van den Munckhof P., et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (1998) 1323-1326
318. Verhagen Metman L., Konitsiotis S., and Chase T.N. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 15 (2000) 3-8
319. Vincken W.G., Gauthier S.G., Dollfuss R.E., et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl J Med 311 (1984) 438-442
320. Volkmann J., Allert N., Voges J., et al. Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 55 (2004) 871-875
321. Waters C.H., Sethi K.D., Hauser R.A., et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 (2004) 426-432
322. Wakabayashi K., Takahashi H., Ohama E., et al. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 60 (1993) 609-612
323. Weiner P., Inzelberg R., Davidovich A., et al. Respiratory muscle performance and the Perception of dyspnea in Parkinson's disease. Can J Neurol Sci 29 (2002) 68-72
324. Winge K., Werdelin L.M., Nielsen K.K., et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 23 (2004) 689-696
325. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59 (2002) 408-413
326. Yeh K.C., August T.F., Bush D.F., et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39 11 Suppl 2 (1989) 25-38
327. Yoshimura N., Mizuta E., Kuno S., et al. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32 (1993) 315-321
328. Yoshimura N., Mizuta E., Yoshida O., et al. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 286 (1998) 228-233
329. Zappia M., Oliveri R.L., Montesanti R., et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 52 (1999) 763-767
330. Zenzola A., Masi G., De Mari M., et al. Fatigue in Parkinson's disease. Neurol Sci 24 (2003) 225-226